Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO,... Read More